Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Lamb Weston reported earnings on October 8 with the stock already up 10.7% on the week to $47.91, and the question now is whether the options defensiveness that dominated the pre-earnings notes finally clears.
The options market has been the story for three consecutive weeks, and it has not fully unwound. The put/call ratio closed at 2.46 on October 6, still running well above its 20-day average of 1.40 and only marginally below the 52-week high of 2.66 touched last week. The z-score of 1.35 puts current put demand about 1.3 standard deviations heavier than usual. That is a notable persistence: the PCR was below 0.60 in mid-September, and a 10.7% weekly gain has brought it down only modestly from peak levels. Some of that lingering put positioning may reflect hedges that were placed before the print and have not yet been closed. Whether it rolls off quickly after the result is the clearest near-term tell on sentiment.
Short interest tells a quieter story. At 4.9% of the free float, it has risen about 20% over the past month, a steady drift rather than a conviction-driven build. Borrow costs remain negligible at 0.51%, and availability is exceptionally loose at 1,648% of short interest, meaning shares available to borrow dwarf the current short position by a wide margin. The lending market carries no squeeze signal. The ORTEX short score of 40.9 sits in the lower half of the universe and has barely moved over the past two weeks, consistent with a stock where shorts are present but not pressing.
Analysts responded to the print with target increases on both sides of the ratings divide. JP Morgan's Thomas Palmer raised his target to $53 from $46 while holding a Neutral rating, after having cut the same target from $52 to $46 just days earlier on September 30. Wells Fargo's Marc Torrente lifted to $58 from $54, maintaining Overweight, reversing a cut to $54 from $57 that came on October 5. The whipsaw in both cases reflects how quickly the pre-earnings pessimism repriced once the result was in. The consensus mean target now sits at $56.09 against a current price of $47.91, leaving implied upside of roughly 17%. The stock trades at 14.2x trailing earnings and 8.5x EV/EBITDA, both up on the week following the bounce. EPS surprise ranks in the 84th percentile, one of the stronger factor scores in the profile, and the dividend score ranks in the 98th percentile, though the dividend history in the data runs only to mid-2022 and should be verified separately.
The ownership picture carries an activist dimension worth noting. Both Jana Partners and Continental Grain have active Schedule 13D filings on Lamb Weston, making this one of the more contested names in the packaged-foods space. Jana's last disclosed stake stood at 4.9% of the class as of July 2025, down from 5.4% previously, while Continental Grain reported 1.5%. As always with 13D disclosures, stakes are as last disclosed around the 5% threshold, and holders can fall below 5% without filing again. BlackRock's passive position has grown to 11.8% and T. Rowe Price to 7.1%, giving the stock a relatively concentrated institutional base. Retail attention is running unusually high: the ORTEX alt data layer shows a Wikipedia views z-score of 2.83 against the stock's own 90-day history, the highest attention reading in the tracked period.
The week after an earnings print with this much pre-event hedging typically resolves in one direction: either the puts are closed quickly as the result is digested, or they roll into the next cycle as investors stay cautious. The PCR and the short interest drift are the two series worth watching most closely in the sessions ahead.
See the live data behind this article on ORTEX.
Open LW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
